Novartis expands India’s role in global drug development and R&D

Novartis is increasing India’s role in its global pharmaceutical research and development (R&D) strategy, shifting focus toward innovative medicines and advanced clinical research. The move follows the sale of its stake in its listed Indian subsidiary to ChrysCapital, allowing the company to concentrate on high-value R&D activities in the country. The company’s Country President, Amitabh Dube, highlighted India’s growing importance in Novartis’ global drug development pipeline, particularly in research, digital capabilities, and clinical operations. Novartis is now prioritizing therapies in oncology, cardiovascular disease, and immunology, aligning with broader industry trends where multinational firms are increasingly using India for high-value R&D beyond manufacturing. Hyderabad and Ahmedabad are key hubs for the expansion, with Novartis strengthening its operations in data science, analytics, and regulatory work. The company is also integrating Indian clinical research into its global programs, citing India’s scientific talent, digital infrastructure, and expanding clinical research ecosystem as critical advantages. India’s biotechnology sector and skilled workforce are attracting more sophisticated pharmaceutical research projects, including specialized therapies like radioligand treatments and precision medicine. Novartis expects rising demand for innovative medicines in India as healthcare infrastructure and accessibility improve, further driving long-term investments in the country’s life sciences ecosystem. The shift positions India as a major player in global pharmaceutical innovation, moving beyond traditional manufacturing roles into advanced drug development. Analysts note this trend reflects broader industry confidence in India’s ability to support high-value research and clinical trials.